Endovascular Treatment of Intracranial Dural Arteriovenous Fistulas: A German Single-Center Experience.
Dural fistulas
Endovascular interventional neuroradiology
Vascular malformations
Vascular radiology
Journal
Cerebrovascular diseases extra
ISSN: 1664-5456
Titre abrégé: Cerebrovasc Dis Extra
Pays: Switzerland
ID NLM: 101577885
Informations de publication
Date de publication:
2020
2020
Historique:
received:
18
05
2020
accepted:
16
06
2020
pubmed:
28
8
2020
medline:
30
9
2020
entrez:
27
8
2020
Statut:
ppublish
Résumé
Intracranial dural arteriovenous fistulas (DAVFs) are abnormal shunts between dural arteries and dural venous sinus or cortical veins. We report our experience with endovascular therapy of primary complex DAVFs using modern embolic agents. This is a retrospective analysis of patients with DAVFs treated between 2015 and 2019. Patient demographics and technical aspects including the use of embolic agent, access to the fistula, number of treatments, occlusion rates, and complications were addressed. Angiographic treatment success was defined as complete occlusion (CO) of the DAVF. Fifty patients were treated endovascularly. Median age was 61 years and 66% were men. The most common symptom was pulsatile tinnitus in 17 patients (34%). The most frequent location of the DAVF was the transverse-sigmoid sinus (40%). Thirty-six fistulas (72%) had cortical venous reflux. Nonadhesive and adhesive liquid agents were used in 92% as a single material or in combination. CO was achieved in 48 patients (96%). In 28 individuals (56%), only 1 procedure was necessary. Nonadhesive liquid agents were exclusively used in 14 patients (28%) with CO attained in every case. For CO of tentorial DAVFs, multiple sessions were more often required than at the other locations (55 vs. 14%, p = 0.0051). Among 93 procedures, the overall complication rate was 3%. The procedure-related mortality rate was 0%. Endovascular treatment of intracranial DAVFs is feasible, safe, and effective with high rates of CO. In more than half of the patients, the DAVF was completely occluded after a single procedure. However, in tentorial DAVFs, multiple sessions were more often required.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
Intracranial dural arteriovenous fistulas (DAVFs) are abnormal shunts between dural arteries and dural venous sinus or cortical veins. We report our experience with endovascular therapy of primary complex DAVFs using modern embolic agents.
METHODS
METHODS
This is a retrospective analysis of patients with DAVFs treated between 2015 and 2019. Patient demographics and technical aspects including the use of embolic agent, access to the fistula, number of treatments, occlusion rates, and complications were addressed. Angiographic treatment success was defined as complete occlusion (CO) of the DAVF.
RESULTS
RESULTS
Fifty patients were treated endovascularly. Median age was 61 years and 66% were men. The most common symptom was pulsatile tinnitus in 17 patients (34%). The most frequent location of the DAVF was the transverse-sigmoid sinus (40%). Thirty-six fistulas (72%) had cortical venous reflux. Nonadhesive and adhesive liquid agents were used in 92% as a single material or in combination. CO was achieved in 48 patients (96%). In 28 individuals (56%), only 1 procedure was necessary. Nonadhesive liquid agents were exclusively used in 14 patients (28%) with CO attained in every case. For CO of tentorial DAVFs, multiple sessions were more often required than at the other locations (55 vs. 14%, p = 0.0051). Among 93 procedures, the overall complication rate was 3%. The procedure-related mortality rate was 0%.
CONCLUSION
CONCLUSIONS
Endovascular treatment of intracranial DAVFs is feasible, safe, and effective with high rates of CO. In more than half of the patients, the DAVF was completely occluded after a single procedure. However, in tentorial DAVFs, multiple sessions were more often required.
Identifiants
pubmed: 32846415
pii: 000509455
doi: 10.1159/000509455
pmc: PMC7548948
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
84-93Informations de copyright
© 2020 The Author(s) Published by S. Karger AG, Basel.
Références
J Neurosurg. 2016 Apr;124(4):1123-7
pubmed: 26406789
Neuroradiology. 2009 Jul;51(7):477-83
pubmed: 19352640
J Neurosurg. 1994 Oct;81(4):531-8
pubmed: 7931586
J Neurosurg. 1995 Feb;82(2):166-79
pubmed: 7815143
Clin Neurol Neurosurg. 2013 Mar;115(3):241-51
pubmed: 23287743
Eur J Radiol. 2003 Jun;46(3):206-20
pubmed: 12758115
J Clin Neurosci. 2018 Mar;49:62-70
pubmed: 29292012
AJNR Am J Neuroradiol. 2013 Sep;34(9):1798-804
pubmed: 23660293
J Neurointerv Surg. 2014 Oct;6(8):607-13
pubmed: 24062253
Neurosurgery. 2014 Feb;74 Suppl 1:S42-9
pubmed: 24402491
Neurosurg Rev. 2014 Jan;37(1):63-71
pubmed: 24101196
J Neurosurg. 1986 May;64(5):724-30
pubmed: 3701421
Radiology. 1995 Mar;194(3):671-80
pubmed: 7862961
Radiology. 1969 Nov;93(5):1071-8
pubmed: 5350675
World Neurosurg. 2013 Jul-Aug;80(1-2):94-102
pubmed: 22381858
J Neurosurg. 1999 Jan;90(1):78-84
pubmed: 10413159
Neuroradiology. 2005 Jul;47(7):543-51
pubmed: 15906020
Radiology. 1981 Jun;139(3):609-16
pubmed: 6165036
J Neurosurg. 2017 Jun;126(6):1884-1893
pubmed: 27588586
Stroke. 1980 Mar-Apr;11(2):210-6
pubmed: 7368251
J Neurointerv Surg. 2013 Jul;5(4):306-10
pubmed: 22550096
Neurosurgery. 2012 Feb;70(2):312-8; discussion 318-9
pubmed: 21822156
Acad Radiol. 2020 Jun;27(6):e123-e131
pubmed: 31445824
Neurosurgery. 1997 Jun;40(6):1133-41; discussion 1141-4
pubmed: 9179885
J Neurosurg. 2019 Jun 28;:1-8
pubmed: 31252394